SARS-CoV-2 pushes MDS enrollment and AML trial to 2021

[cheng_ho]

https://ir.geron.com/investors/press-re ... fault.aspx

Obviously, most patients will be suspending infusions until the epidemic (and the response to the epidemic, which is even more harmful) are over.

This will make it hard to use data, as infusion schedules will be different between different patients. Also, more patients will die before the end of the study, so they'll need to enroll more patients.

Maybe this time NIH will manage to keep its attention span long enough to finish some SARS studies... that didn't happen with SARS 1, though.